Q-omics provides the consensus-scored TEX35 profile across patient tissues and cancer cell-line models. TEX35 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TEX35 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, TEX35 RNA expression shows 9,179 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, KICH, and THYM as cancer lineages where TEX35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX35 survival associations across molecular data types. TEX35 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX35 RNA expression–survival associations across cancer types. High TEX35 expression shows unfavorable associations in SCLC, UCEC, ESCA and CHOL, but favorable associations in CESC and LUSC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TEX35 RNA expression.
This table summarizes TEX35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TEX35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX35 shows lower tumor expression in KICH and higher tumor expression in LUSC, BRCA, CHOL, LUAD and LIHC. The KICH box plot shows higher TEX35 RNA expression in normal versus tumor tissue (log2 FC = −0.027, t-test p = .001).
This table shows molecular features associated with TEX35 in patient tissues and cancer cell lines. In patient samples, TEX35 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
